{"title":"1,3,4-Oxadiazole derivatives: targeting multiple bacterial pathways","authors":"Pankaj Gupta, Sangeeta Verma, Rakesh Narang, Bhupesh Sharma, Vikramjeet Singh and Sukhbir Lal","doi":"10.1039/D5MD01139F","DOIUrl":null,"url":null,"abstract":"<p >Antimicrobial resistance (AMR) has emerged as a major worldwide issue in the effective management of infectious diseases. This problem prompted researchers worldwide to develop new therapeutic agents that target both well-established and novel biological pathways. Among numerous heterocyclic frameworks, 1,3,4-oxadiazole compounds have attracted considerable attention due to their diverse pharmacological activities. The incorporation of a 1,3,4-oxadiazole ring into antimicrobial agents enhances their flexibility and polarity, thereby improving interactions at the molecular level. Different research reports have indicated that these types of compounds exhibit potential interactions, such as hydrogen bonding, electrostatic forces, steric effects, and hydrophobic interactions, which contribute to enhancing their antibacterial efficacy by facilitating better binding with microbial targets. Reported data indicated that 1,3,4-oxadiazole-based compounds exhibited antibacterial activity through inhibition of various essential bacterial cell components or pathways, <em>viz.</em>, cell division, cell wall synthesis, proteolytic enzymes, folate, cofactors, lipids or fatty acids, ribosomes, detoxification and resistance inducers, virulence and pathogenicity, <em>etc.</em> The present study consolidates recent advances in SAR analysis and various binding modes of 1,3,4-oxadiazole derivatives as antibacterial agents, published between 2021 and 2025. This information will be beneficial for researchers in the development of novel antibacterial molecules based on the 1,3,4-oxadiazole moiety.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 4","pages":" 1867-1887"},"PeriodicalIF":3.5970,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2026/md/d5md01139f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Antimicrobial resistance (AMR) has emerged as a major worldwide issue in the effective management of infectious diseases. This problem prompted researchers worldwide to develop new therapeutic agents that target both well-established and novel biological pathways. Among numerous heterocyclic frameworks, 1,3,4-oxadiazole compounds have attracted considerable attention due to their diverse pharmacological activities. The incorporation of a 1,3,4-oxadiazole ring into antimicrobial agents enhances their flexibility and polarity, thereby improving interactions at the molecular level. Different research reports have indicated that these types of compounds exhibit potential interactions, such as hydrogen bonding, electrostatic forces, steric effects, and hydrophobic interactions, which contribute to enhancing their antibacterial efficacy by facilitating better binding with microbial targets. Reported data indicated that 1,3,4-oxadiazole-based compounds exhibited antibacterial activity through inhibition of various essential bacterial cell components or pathways, viz., cell division, cell wall synthesis, proteolytic enzymes, folate, cofactors, lipids or fatty acids, ribosomes, detoxification and resistance inducers, virulence and pathogenicity, etc. The present study consolidates recent advances in SAR analysis and various binding modes of 1,3,4-oxadiazole derivatives as antibacterial agents, published between 2021 and 2025. This information will be beneficial for researchers in the development of novel antibacterial molecules based on the 1,3,4-oxadiazole moiety.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.